Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 73
Selected: 0
NCT IDTitle
NCT04548869A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria
NCT03804944Converting HR+ Breast Cancer Into an Individualized Vaccine
NCT01997333Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
NCT03789097Vaccination With Flt3L, Radiation, and Poly-ICLC
NCT02166905DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
NCT01156753A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
NCT05349890Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
NCT01498328A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
NCT06455202A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT03329950A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
NCT02200380A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
NCT04440943A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
NCT07256392Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT06650761A Phase I Study of CDX-622
NCT01791686Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease
NCT04364230Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)
NCT00412828A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma
NCT07330778A Study of CDX-622 in Participants With Mild to Moderate Asthma
NCT05031624A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects
NCT05774184A Study of CDX-0159 in Patients With Eosinophilic Esophagitis
NCT02839265FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer
NCT02386111A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
NCT01460134A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
NCT04538794A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
NCT05029999CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
NCT04491084FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy
NCT05231122Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
NCT01465139A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers
NCT03835533Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations
NCT02413827A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
NCT02837991A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
NCT07266402A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
NCT03580382Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma
NCT03617328Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma
NCT02543645A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
NCT04146129A Phase 1 Study of CDX-0159
NCT02642016A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors
NCT02270372Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer
NCT00948961A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
NCT02456701Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
NCT02302339A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
NCT02335918A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
NCT00323518A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis
NCT06445023A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT04536077Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
NCT03688178DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab
NCT03254927A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma
NCT01976585In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy
NCT06727552A Study of Barzolvolimab in Patients With Atopic Dermatitis
NCT03068650Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut